Nasdaq Halts Charming Medical Limited
Nasdaq (Nasdaq: NDAQ) announced a trading halt in Charming Medical Limited (Nasdaq: MCTA) while Nasdaq requests additional information from the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nasdaq (Nasdaq: NDAQ) announced a trading halt in Charming Medical Limited (Nasdaq: MCTA) while Nasdaq requests additional information from the company.
The Securities and Exchange Commission previously suspended trading in MCTA from 04:00:00 on November 12, 2025 to 23:59:00 on November 25, 2025. The company\'s last reported sale price was $29.355. Trading will remain halted until Charming Medical Limited fully satisfies Nasdaq\'s information request. The SEC order is available at the SEC website linked in the announcement.
Positive
- SEC trading suspension ended on Nov 25, 2025
- Last reported share price was $29.355
Negative
- Nasdaq trading halt remains in effect pending additional information
- Prior SEC suspension covered Nov 12, 2025 to Nov 25, 2025
Details
News Market Reaction – NDAQ
On Nov 26, the day this news came out, NDAQ closed 0.94% above the previous close.
Data tracked by StockTitan Argus for the Nov 26 session.
Key Figures
- MCTA last sale price
- $29.355
- Last reported sale price before SEC suspension window
- SEC suspension start
- 04:00:00 on November 12, 2025
- Start of SEC trading suspension in MCTA
- SEC suspension end
- 23:59:00 on November 25, 2025
- End of SEC trading suspension in MCTA
- NDAQ pre-news price
- $93.85
- NDAQ price before Nasdaq’s halt announcement on MCTA
- NDAQ 52-week high
- $97.63
- Pre-news 52-week high level
- NDAQ 52-week low
- $64.84
- Pre-news 52-week low level
- Shares registered S-8
- 7,500,000 shares
- Additional NDAQ common shares for equity incentive plan (Form S-8)
- Q3 2025 revenue
- $1.958 billion
- NDAQ revenues for Q3 2025 from Form 10-Q
Historical Context
-
Report of end-of-month open short interest across all Nasdaq securities.
-
Walmart common stock and bonds begin trading on Nasdaq after transfer.
-
Release of November 2025 trading volumes and detailed statistics data sheet.
-
Announcement of presentation at Goldman Sachs 2025 Financial Services Conference.
-
Nasdaq halts MaxsMaking Inc. (MAMK) pending additional requested information.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
trading is halted financial
trading suspension regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Charming Medical Limited (Nasdaq: MCTA) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in MCTA from 04:00:00 on November 12, 2025 to 23:59:00 on November 25, 2025. The last sale price of the company’s ordinary shares was
More information about the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104176.pdf.
Trading will remain halted until Charming Medical Limited has fully satisfied Nasdaq’s request for additional information.
For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.
Nasdaq Contact:
Nasdaq MarketWatch
nasdaqmarketwatch@nasdaq.com
NDAQO
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.